204 related articles for article (PubMed ID: 32536947)
1. Anaphylaxis to three humanized antibodies for severe asthma: a case study.
Jingo K; Harada N; Nishioki T; Torasawa M; Yamada T; Asao T; Takagi H; Takeshige T; Ito J; Takahashi K
Allergy Asthma Clin Immunol; 2020; 16():46. PubMed ID: 32536947
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of tezepelumab against uncontrolled severe non-type 2 asthma refractory to bronchial thermoplasty, benralizumab, dupilumab and mepolizumab.
Kai Y; Suzuki K; Kataoka R; Sato I; Tamaki S; Muro S
Respirol Case Rep; 2024 Mar; 12(3):e01311. PubMed ID: 38420113
[TBL] [Abstract][Full Text] [Related]
3. A patient case demonstrating the efficacy of benralizumab in uncontrolled severe eosinophilic asthma refractory to omalizumab and mepolizumab treatment.
Davison J; Doe S
Respir Med Case Rep; 2021; 34():101557. PubMed ID: 34877251
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma.
Agache I; Beltran J; Akdis C; Akdis M; Canelo-Aybar C; Canonica GW; Casale T; Chivato T; Corren J; Del Giacco S; Eiwegger T; Firinu D; Gern JE; Hamelmann E; Hanania N; Mäkelä M; Hernández-Martín I; Nair P; O'Mahony L; Papadopoulos NG; Papi A; Park HS; Pérez de Llano L; Posso M; Rocha C; Quirce S; Sastre J; Shamji M; Song Y; Steiner C; Schwarze J; Alonso-Coello P; Palomares O; Jutel M
Allergy; 2020 May; 75(5):1023-1042. PubMed ID: 32034960
[TBL] [Abstract][Full Text] [Related]
5. Clinical characteristics of complete responders versus non-complete responders to omalizumab, benralizumab and mepolizumab in patients with severe asthma: a long-term retrospective analysis.
Basagaña M; Martínez-Rivera C; Padró C; Garcia-Olivé I; Martínez-Colls M; Navarro J; Pardo L; Cruz P; Cardona Peitx G; Carabias L; Roger A; Abad J; Rosell A
Ann Med; 2024 Dec; 56(1):2317356. PubMed ID: 38364218
[TBL] [Abstract][Full Text] [Related]
6. Smaller Differences in the Comparative Effectiveness of Biologics in Reducing Asthma-Related Hospitalizations Compared With Overall Exacerbations.
Akenroye A; Marshall J; Simon AL; Hague C; Costa R; Jamal-Allial A; McMahill-Walraven CN; Haffenreffer K; Han A; Wu AC
J Allergy Clin Immunol Pract; 2024 Jun; 12(6):1568-1574.e2. PubMed ID: 38431251
[TBL] [Abstract][Full Text] [Related]
7. Comparative Effectiveness of Mepolizumab, Benralizumab, and Dupilumab among Patients with Difficult-to-Control Asthma: A Multicenter Retrospective Propensity-matched Analysis.
Kearney CM; Sangani R; Shankar D; O'Connor GT; Law AC; Walkey AJ; Bosch NA
Ann Am Thorac Soc; 2024 Jun; 21(6):866-874. PubMed ID: 38241013
[No Abstract] [Full Text] [Related]
8. Anaphylactic risk related to omalizumab, benralizumab, reslizumab, mepolizumab, and dupilumab.
Li L; Wang Z; Cui L; Xu Y; Guan K; Zhao B
Clin Transl Allergy; 2021 Jun; 11(4):e12038. PubMed ID: 34123366
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness analysis of dupilumab versus omalizumab, mepolizumab, and benralizumab added to the standard of care in adults with severe asthma in Colombia.
Ali A; García E; Torres-Duque CA; Rey D; Botero L; Saenz S; Avila MP; Mazo E; Londoño S
Expert Rev Pharmacoecon Outcomes Res; 2024 Mar; 24(3):361-374. PubMed ID: 37994432
[TBL] [Abstract][Full Text] [Related]
10. Mabs for treating asthma: omalizumab, mepolizumab, reslizumab, benralizumab, dupilumab.
Ridolo E; Pucciarini F; Nizi MC; Makri E; Kihlgren P; Panella L; Incorvaia C
Hum Vaccin Immunother; 2020 Oct; 16(10):2349-2356. PubMed ID: 32401603
[TBL] [Abstract][Full Text] [Related]
11. A cost comparison of benralizumab, mepolizumab, and dupilumab in patients with severe asthma: A US third-party payer perspective.
Xu X; Schaefer C; Szende A; Genofre E; Katial R; Chung Y
J Manag Care Spec Pharm; 2023 Nov; 29(11):1193-1204. PubMed ID: 37796731
[No Abstract] [Full Text] [Related]
12. Anti-IL5 therapies for asthma.
Farne HA; Wilson A; Powell C; Bax L; Milan SJ
Cochrane Database Syst Rev; 2017 Sep; 9(9):CD010834. PubMed ID: 28933516
[TBL] [Abstract][Full Text] [Related]
13. Biologics in allergic rhinitis.
Bayar Muluk N; Cingi C
Eur Rev Med Pharmacol Sci; 2023 Oct; 27(5 Suppl):43-52. PubMed ID: 37869947
[TBL] [Abstract][Full Text] [Related]
14. Real-Life Effectiveness of Benralizumab, Mepolizumab and Omalizumab in Severe Allergic Asthma Associated with Nasal Polyps.
Tiotiu A; Mendez-Brea P; Ioan I; Romero-Fernandez R; Oster JP; Hoang TC; Roux P; Ochoa-Gutierrez DC; Bonniaud P; de Blay F; Gonzalez-Barcala FJ
Clin Rev Allergy Immunol; 2023 Apr; 64(2):179-192. PubMed ID: 35420388
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness analysis of dupilumab among patients with oral corticosteroid-dependent uncontrolled severe asthma in Japan.
Tohda Y; Matsumoto H; Miyata M; Taguchi Y; Ueyama M; Joulain F; Arakawa I
J Asthma; 2022 Nov; 59(11):2162-2173. PubMed ID: 34752208
[TBL] [Abstract][Full Text] [Related]
16. Matching-adjusted comparison of oral corticosteroid reduction in asthma: Systematic review of biologics.
Bourdin A; Husereau D; Molinari N; Golam S; Siddiqui MK; Lindner L; Xu X
Clin Exp Allergy; 2020 Apr; 50(4):442-452. PubMed ID: 31943429
[TBL] [Abstract][Full Text] [Related]
17. Dual biologics for severe asthma and atopic dermatitis: Synopsis of two cases and literature review.
Matsumoto T; Sakurai Y; Tashima N; Matoba T; Kaneko A; Fujiki T; Kusakabe Y; Nakayama E; Tanaka A; Tashima M; Yamamoto N; Aihara K
Respirol Case Rep; 2024 Jan; 12(1):e01266. PubMed ID: 38074921
[TBL] [Abstract][Full Text] [Related]
18. Anti-IL-5 therapies for asthma.
Farne HA; Wilson A; Milan S; Banchoff E; Yang F; Powell CV
Cochrane Database Syst Rev; 2022 Jul; 7(7):CD010834. PubMed ID: 35838542
[TBL] [Abstract][Full Text] [Related]
19. [A CASE OF SEVERE ASTHMA SWITCHED TO MEPOLIZUMAB DUE TO LATE-OCCURRING UNRESPONSIVENESS TO BENRALIZUMAB].
Matsumoto-Sasaki M; Shimizu K; Suzuki M; Suzuki M; Nakamaru Y; Konno S
Arerugi; 2020; 69(8):678-682. PubMed ID: 32963191
[TBL] [Abstract][Full Text] [Related]
20. Clinical and Lung Function Outcomes After Anti-IgE or Anti-IL5 Therapy in Severe Asthma.
AlShareef S; McDonald CF; Lee J
J Asthma Allergy; 2022; 15():209-217. PubMed ID: 35210787
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
